NMD Pharma Gets FDA IND Approval to Start Phase 2 Study of NMD670 in US for Charcot-Marie-Tooth Disease.

The U.S. Food and Drug Administration (FDA) approved Darolutamide, marketed under the brand name Nubeqa, on July 30, 2019.

Mozart Therapeutics Administers Initial Dose in Phase 1 Clinical Study of MTX-101 for Autoimmune Disease Therapy.

The U.S. Food and Drug Administration (FDA) approved Recarbrio, which is a combination of imipenem, cilastatin, and relebactam, on July 16, 2019.

Zymeworks Receives FDA Approval for ZW171, a New Bispecific Antibody Targeting Mesothelin-related Tumors.

The U.S. Food and Drug Administration (FDA) approved amlodipine, which is marketed under brand names such as Norvasc, Katerzia, and Norliqva, for medical use. This approval was granted on July 8, 2019.

iTeos and GSK Launch Phase 3 GALAXIES Lung-301 Trial, Evaluating Belrestotug and Dostarlimab in Untreated, Inoperable Advanced/Metastatic PD-L1 Positive Non-Small Cell Lung Cancer.

The U.S. Food and Drug Administration (FDA) granted approval for selinexor on an accelerated basis on July 3, 2019.

Kira Pharmaceuticals Shares Encouraging KP104 Phase 2 PNH Trial Outcomes at 2024 EHA Congress, Highlighting Sustained Safety and Effectiveness.

bremelanotide, marketed under the brand name Vyleesi, is FDA approved. The FDA granted approval for bremelanotide on June 21, 2019.

A Biologics License Application for subcutaneous amivantamab was submitted to the U.S. FDA for people with non-small cell lung cancer with EGFR mutations.

The study indicated that Retatrutide (LY3437943), a GLP-1R-related triple receptor agonist currently under clinical development, demonstrated significant efficacy and favorable safety in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD).